Mr. French serves on the board of directors of several start-up life science companies based in Indiana: On Target Laboratories (Chairman), Anagin, and FAST BioMedical.
Mr. French was a co-founder and CEO of Calibrium, a start-up biopharmaceutical company focused on developing therapeutics for the treatment of diabetes and obesity. Calibrium was sold to Novo Nordisk in late 2015. Previously, he was CEO of Marcadia Biotech, another start-up biopharmaceutical company in the diabetes and obesity area, from company inception until just after sale to Roche in 2010. Prior to Marcadia, Mr. French was Vice President, Global Marketing for the Vascular Intervention division (now part of Abbott) of Guidant Corporation (acquired by Boston Scientific) and immediately prior to this, he held the role of Vice President, Corporate Marketing and Communications.
Mr. French also served as President and CEO of two life science start-up companies, Corvascular, Inc. and Zephyr Medical. He had previously worked at Guidant and the Medical Devices and Diagnostic Division of Lilly, serving in numerous marketing, sales, and general management positions for Lilly and Guidant, both in the U.S. and Europe.
He also serves on the board of trustees of Marian University and the board of directors of Meridian Hills Country Club. He has previously served on several community organization boards and currently serves as a volunteer at Catholic Charities of Indianapolis.
Mr. French earned a B.S. from the Kelley School of Business, Indiana University, and an M.B.A. from Harvard Business School, Harvard University. He and his wife, Shele, have two children, Julia, who is a student at Marian University, and Michael, who is a student at the University of Miami.